CCRN
CCRN
Cross Country Healthcare, Inc.Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $250.05M ▼ | $56.9M ▼ | $-4.77M ▲ | -1.91% ▲ | $-0.15 ▲ | $-993K ▲ |
| Q2-2025 | $274.07M ▼ | $61.86M ▲ | $-6.66M ▼ | -2.43% ▼ | $-0.2 ▼ | $-1.08M ▼ |
| Q1-2025 | $293.41M ▼ | $59.63M ▼ | $-490K ▲ | -0.17% ▲ | $-0.02 ▲ | $4.42M ▲ |
| Q4-2024 | $309.94M ▼ | $65.42M ▲ | $-3.75M ▼ | -1.21% ▼ | $-0.12 ▼ | $3.98M ▼ |
| Q3-2024 | $315.12M | $61.3M | $2.56M | 0.81% | $0.08 | $8.44M |
What's going well?
The company reduced its net loss by nearly $2 million and improved EPS, showing some cost control. Interest costs are low, and there are no major one-time charges distorting results.
What's concerning?
Revenue and gross profit both dropped sharply, and the business remains unprofitable. Margins are thin, and there's no sign of a turnaround in core profitability.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $99.13M ▲ | $538.23M ▼ | $130.09M ▼ | $408.14M ▼ |
| Q2-2025 | $81.19M ▲ | $553.82M ▼ | $141.58M ▼ | $412.24M ▼ |
| Q1-2025 | $80.7M ▼ | $576.24M ▼ | $158.03M ▼ | $418.21M ▼ |
| Q4-2024 | $81.63M ▲ | $589.25M ▼ | $170.29M ▼ | $418.96M ▼ |
| Q3-2024 | $64.02M | $597.42M | $172.73M | $424.69M |
What's financially strong about this company?
The company has a big cash cushion, almost no debt, and can easily pay its bills. Receivables are coming in faster, and there’s a long track record of profits. The asset base is mostly high-quality and liquid.
What are the financial risks or weaknesses?
Shareholder equity dipped slightly, and a quarter of assets are goodwill and intangibles, which could be written down if business weakens. No deferred revenue means less upfront cash from customers.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-4.77M ▲ | $20.11M ▲ | $-2.19M ▼ | $-6K ▲ | $17.94M ▲ | $17.92M ▲ |
| Q2-2025 | $-6.66M ▼ | $4.22M ▼ | $-1.97M ▼ | $-1.76M ▲ | $496K ▲ | $2.25M ▼ |
| Q1-2025 | $-490K ▲ | $5.68M ▼ | $-1.89M ▲ | $-4.72M ▼ | $-936K ▼ | $3.79M ▼ |
| Q4-2024 | $-3.75M ▼ | $24.23M ▲ | $-2.53M ▼ | $-4.08M ▲ | $17.61M ▲ | $21.7M ▲ |
| Q3-2024 | $2.56M | $7.47M | $-1.12M | $-11.93M | $-5.58M | $6.35M |
What's strong about this company's cash flow?
The company turned a net loss into $20 million of operating cash and $18 million of free cash flow. Cash reserves are growing, and there's no need for outside funding.
What are the cash flow concerns?
Much of the cash surge came from a one-time boost in collecting receivables, not from ongoing profits. Net income is still negative, and this level of cash generation may not repeat.
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
Other Services | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
Q3 2024 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at Cross Country Healthcare, Inc.'s financial evolution and strategic trajectory over the past five years.
The company’s biggest strengths are its significantly improved balance sheet, strong liquidity, and demonstrated ability to generate free cash flow in good years. It has transformed itself from a more leveraged operator into a net‑cash, low‑debt business with ample short‑term resources. On the commercial side, its integrated workforce solutions, proprietary Intellify platform, and presence across hospital, homecare, and education markets provide multiple ways to create value for clients and avoid relying solely on one segment or product line.
The main risks center on the income statement and industry dynamics. Revenue and profits have fallen sharply from their 2022 peak, and the business is currently loss‑making at the net level, indicating that the cost base still does not match the new reality of demand and pricing. Competitive pressure, client cost‑cutting, and the broader normalization of contingent staffing after the pandemic surge could keep growth and margins under strain. Volatile cash flows driven by working capital swings and the strategic reset after the canceled Aya merger add further uncertainty.
Looking ahead, the company appears financially sturdy but operationally challenged. Its strong liquidity and low leverage give it time and flexibility to adjust, while its technology platform and diversified services offer paths to rebuild more sustainable, less cyclical earnings. The outlook will depend on how quickly management can stabilize revenue, restore margin discipline, and prove that its tech‑enabled, integrated model can deliver clear cost and quality benefits to clients in a tougher, more normalized market environment.
About Cross Country Healthcare, Inc.
https://www.crosscountryhealthcare.comCross Country Healthcare, Inc. provides talent management and other consultative services for healthcare clients in the United States. The company operates in two segments, Nurse and Allied Staffing and Physician Staffing.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $250.05M ▼ | $56.9M ▼ | $-4.77M ▲ | -1.91% ▲ | $-0.15 ▲ | $-993K ▲ |
| Q2-2025 | $274.07M ▼ | $61.86M ▲ | $-6.66M ▼ | -2.43% ▼ | $-0.2 ▼ | $-1.08M ▼ |
| Q1-2025 | $293.41M ▼ | $59.63M ▼ | $-490K ▲ | -0.17% ▲ | $-0.02 ▲ | $4.42M ▲ |
| Q4-2024 | $309.94M ▼ | $65.42M ▲ | $-3.75M ▼ | -1.21% ▼ | $-0.12 ▼ | $3.98M ▼ |
| Q3-2024 | $315.12M | $61.3M | $2.56M | 0.81% | $0.08 | $8.44M |
What's going well?
The company reduced its net loss by nearly $2 million and improved EPS, showing some cost control. Interest costs are low, and there are no major one-time charges distorting results.
What's concerning?
Revenue and gross profit both dropped sharply, and the business remains unprofitable. Margins are thin, and there's no sign of a turnaround in core profitability.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $99.13M ▲ | $538.23M ▼ | $130.09M ▼ | $408.14M ▼ |
| Q2-2025 | $81.19M ▲ | $553.82M ▼ | $141.58M ▼ | $412.24M ▼ |
| Q1-2025 | $80.7M ▼ | $576.24M ▼ | $158.03M ▼ | $418.21M ▼ |
| Q4-2024 | $81.63M ▲ | $589.25M ▼ | $170.29M ▼ | $418.96M ▼ |
| Q3-2024 | $64.02M | $597.42M | $172.73M | $424.69M |
What's financially strong about this company?
The company has a big cash cushion, almost no debt, and can easily pay its bills. Receivables are coming in faster, and there’s a long track record of profits. The asset base is mostly high-quality and liquid.
What are the financial risks or weaknesses?
Shareholder equity dipped slightly, and a quarter of assets are goodwill and intangibles, which could be written down if business weakens. No deferred revenue means less upfront cash from customers.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-4.77M ▲ | $20.11M ▲ | $-2.19M ▼ | $-6K ▲ | $17.94M ▲ | $17.92M ▲ |
| Q2-2025 | $-6.66M ▼ | $4.22M ▼ | $-1.97M ▼ | $-1.76M ▲ | $496K ▲ | $2.25M ▼ |
| Q1-2025 | $-490K ▲ | $5.68M ▼ | $-1.89M ▲ | $-4.72M ▼ | $-936K ▼ | $3.79M ▼ |
| Q4-2024 | $-3.75M ▼ | $24.23M ▲ | $-2.53M ▼ | $-4.08M ▲ | $17.61M ▲ | $21.7M ▲ |
| Q3-2024 | $2.56M | $7.47M | $-1.12M | $-11.93M | $-5.58M | $6.35M |
What's strong about this company's cash flow?
The company turned a net loss into $20 million of operating cash and $18 million of free cash flow. Cash reserves are growing, and there's no need for outside funding.
What are the cash flow concerns?
Much of the cash surge came from a one-time boost in collecting receivables, not from ongoing profits. Net income is still negative, and this level of cash generation may not repeat.
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
Other Services | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
Q3 2024 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at Cross Country Healthcare, Inc.'s financial evolution and strategic trajectory over the past five years.
The company’s biggest strengths are its significantly improved balance sheet, strong liquidity, and demonstrated ability to generate free cash flow in good years. It has transformed itself from a more leveraged operator into a net‑cash, low‑debt business with ample short‑term resources. On the commercial side, its integrated workforce solutions, proprietary Intellify platform, and presence across hospital, homecare, and education markets provide multiple ways to create value for clients and avoid relying solely on one segment or product line.
The main risks center on the income statement and industry dynamics. Revenue and profits have fallen sharply from their 2022 peak, and the business is currently loss‑making at the net level, indicating that the cost base still does not match the new reality of demand and pricing. Competitive pressure, client cost‑cutting, and the broader normalization of contingent staffing after the pandemic surge could keep growth and margins under strain. Volatile cash flows driven by working capital swings and the strategic reset after the canceled Aya merger add further uncertainty.
Looking ahead, the company appears financially sturdy but operationally challenged. Its strong liquidity and low leverage give it time and flexibility to adjust, while its technology platform and diversified services offer paths to rebuild more sustainable, less cyclical earnings. The outlook will depend on how quickly management can stabilize revenue, restore margin discipline, and prove that its tech‑enabled, integrated model can deliver clear cost and quality benefits to clients in a tougher, more normalized market environment.

CEO
John A. Martins
Compensation Summary
(Year 2024)
Upcoming Earnings
ETFs Holding This Stock
Summary
Showing Top 3 of 90
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:5.92M
Value:$51.54M
BLACKROCK, INC.
Shares:2.62M
Value:$22.81M
BLACKROCK FUND ADVISORS
Shares:2.61M
Value:$22.75M
Summary
Showing Top 3 of 260

